Ahmed Ali Khan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ahmed Ali Khan has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Haider Imran
Foundation University Medical College, Islamabad, Pakistan
4 shared publications - Danish Ali Ashraf
Foundation University Medical College
3 shared publications - Aamna Raheel Sheikh
Foundation University Medical College, Rawalpindi, Pakistan
2 shared publications - Asher Tariq
Foundation University Medical College, Islamabad, Pakistan
2 shared publications - Atifa Kanwal
Shaheed Mohtarma Benazir Bhutto Medical College, Lyari, Karachi, Pakistan
2 shared publications - Eshal Fatima
Aga Khan Medical College, Karachi, Pakistan
2 shared publications
Latest Publications
- 29 July 2026
- Published by Springer Nature in Osteoporosis International
- Vol. 37 (10) , 2605-2615
Comparative efficacy of biosimilar denosumab and reference denosumab in treatment of postmenopausal osteoporosis: a systematic review and meta-analysis
- 29 July 2026
- Published by Springer Nature in Osteoporosis International
- Vol. 37 (10) , 2605-2615
Comparative efficacy of biosimilar denosumab and reference denosumab in treatment of postmenopausal osteoporosis: a systematic review and meta-analysis
- 14 June 2026
- Published by Elsevier in Sleep Medicine
- Vol. 146, 109084
Non-rapid eye movement parasomnias and sleep quality among medical students: Implications for academic performance: A cross-sectional survey
- 14 June 2026
- Published by Elsevier in Sleep Medicine
- Vol. 146, 109084
Non-rapid eye movement parasomnias and sleep quality among medical students: Implications for academic performance: A cross-sectional survey
- Open Access
- 30 May 2026
- Published by The Korean Society of Gastrointestinal Endoscopy in Clinical Endoscopy
- Vol. 59 (3) , 371-385
Enhanced adenoma detection with Endocuff Vision: a GRADE assessed systematic review and meta-analysis
Background/Aims: Colorectal cancer (CRC) is the second leading cause of cancer-related deaths and the third most common cancer worldwide. Detecting adenomas during colonoscopy reduces the CRC risk, with higher adenoma detection rates (ADRs) correlating with lower CRC incidence and mortality. Endocuff Vision (EV) enhances mucosal visualization and may improve ADRs. Methods: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines, PubMed, Embase, and Cochrane databases were searched through April 2025 for studies comparing EV-assisted and standard colonoscopy. The primary outcomes of interest were the ADRs, polyp detection rates (PDRs), and adverse events (AEs). Outcomes were pooled using a random-effects meta-analysis model and are presented as risk ratios (RRs) and mean differences. Heterogeneity in the pooled outcomes was assessed using the Higgins I². Results: Thirty-four studies (43,702 participants) were included. EV significantly improved ADRs (RR, 1.15; 95% confidence interval [CI],1.07–1.25) and PDRs (RR, 1.16; 95% CI, 1.10–1.23). EV also improved lesion detection in the left colon (RR, 1.23; 95% CI, 1.11–1.35) and right colon (RR, 1.19; 95% CI, 1.09–1.29). No significant improvement was observed in advanced ADRs or cecal intubation. EV use was associated with more AEs.Conclusions: EV-assisted colonoscopy improved ADRs and PDRs in both colonic regions and enhanced CRC screening despite increased AEs.
- 30 May 2026
- Published by The Korean Society of Gastrointestinal Endoscopy in Clinical Endoscopy
- Vol. 59 (3) , 371-385
Open AccessEnhanced adenoma detection with Endocuff Vision: a GRADE assessed systematic review and meta-analysis
Background/Aims: Colorectal cancer (CRC) is the second leading cause of cancer-related deaths and the third most common cancer worldwide. Detecting adenomas during colonoscopy reduces the CRC risk, with higher adenoma detection rates (ADRs) correlating with lower CRC incidence and mortality. Endocuff Vision (EV) enhances mucosal visualization and may improve ADRs. Methods: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines, PubMed, Embase, and Cochrane databases were searched through April 2025 for studies comparing EV-assisted and standard colonoscopy. The primary outcomes of interest were the ADRs, polyp detection rates (PDRs), and adverse events (AEs). Outcomes were pooled using a random-effects meta-analysis model and are presented as risk ratios (RRs) and mean differences. Heterogeneity in the pooled outcomes was assessed using the Higgins I². Results: Thirty-four studies (43,702 participants) were included. EV significantly improved ADRs (RR, 1.15; 95% confidence interval [CI],1.07–1.25) and PDRs (RR, 1.16; 95% CI, 1.10–1.23). EV also improved lesion detection in the left colon (RR, 1.23; 95% CI, 1.11–1.35) and right colon (RR, 1.19; 95% CI, 1.09–1.29). No significant improvement was observed in advanced ADRs or cecal intubation. EV use was associated with more AEs.Conclusions: EV-assisted colonoscopy improved ADRs and PDRs in both colonic regions and enhanced CRC screening despite increased AEs.
- 30 December 2025
- Published by Elsevier in Asian Journal of Psychiatry
- Vol. 116, 104808
Effect of quetiapine versus haloperidol on delirium severity in hospitalized adults: A systematic review and meta‑analysis
- 30 December 2025
- Published by Elsevier in Asian Journal of Psychiatry
- Vol. 116, 104808
Effect of quetiapine versus haloperidol on delirium severity in hospitalized adults: A systematic review and meta‑analysis
- 4 May 2025
- Published by Springer Nature in International Urology and Nephrology
- Vol. 57 (11) , 3671-3685
Role of nicorandil in preventing contrast-induced nephropathy in patients undergoing cardiac catheterization procedures: an updated systematic review and meta-analysis
Background Contrast-induced nephropathy (CIN) is a major risk for patients undergoing coronary angiography (CAG) and percutaneous coronary intervention (PCI). Methods PubMed, MEDLINE, Embase, Google Scholar, and Web of Science were searched through May 2024 to include randomized controlled trials (RCTs) assessing the efficacy and safety of nicorandil administration in patients following CAG or PCI. Outcomes of interest included the CIN incidence, major adverse events, serum creatinine, serum cystatin C, BUN and eGFR. Risk ratios (RRs) and standard mean differences (SMDs) with 95% confidence intervals (CIs) were calculated using random-effects model. Statistical heterogeneity was assessed using I2 statistics. Results Twelve studies (n = 2931 patients) were included in the final analysis. Nicorandil significantly reduced the CIN incidence (RR: 0.40 [0.31,0.52]; p < 0.00001), with consistent results for oral (RR: 0.35 [0.25,0.48]; p < 0.00001) and intravenous administration (RR: 0.52 [0.30,0.92]; p = 0.02) (p-interaction = 0.22). Oral nicorandil reduced the risk of major adverse events (RR: 0.71 [0.51,0.99]; p = 0.05). Among patients on nicorandil, serum creatinine levels were significantly lower at 48 h (SMD: −0.30 [−0.52,−0.07]; p = 0.009), and 72 h post-intervention (SMD: −0.42 [−0.71,−0.13]; p = 0.004). Nicorandil significantly reduced serum cystatin C levels at 48 h post-intervention (SMD: -0.56 [−1.01,−0.01]; p = 0.02). However, nicorandil did not significantly affect eGFR values at 24-h (SMD: 0.12 [−0.21,0.45]; p = 0.46), 48-h (SMD: 0.08 [−0.19,0.35]; p = 0.58), and 72-h (SMD: 0.34 [−0.13,0.81]; p = 0.16). Conclusion Nicorandil administration reduces the CIN incidence and improves renal biomarkers in patients undergoing CAG and PCI. Large-scale trials with longer follow-up periods are warranted to confirm renoprotective effects of nicorandil.
- 4 May 2025
- Published by Springer Nature in International Urology and Nephrology
- Vol. 57 (11) , 3671-3685
Role of nicorandil in preventing contrast-induced nephropathy in patients undergoing cardiac catheterization procedures: an updated systematic review and meta-analysis
Background Contrast-induced nephropathy (CIN) is a major risk for patients undergoing coronary angiography (CAG) and percutaneous coronary intervention (PCI). Methods PubMed, MEDLINE, Embase, Google Scholar, and Web of Science were searched through May 2024 to include randomized controlled trials (RCTs) assessing the efficacy and safety of nicorandil administration in patients following CAG or PCI. Outcomes of interest included the CIN incidence, major adverse events, serum creatinine, serum cystatin C, BUN and eGFR. Risk ratios (RRs) and standard mean differences (SMDs) with 95% confidence intervals (CIs) were calculated using random-effects model. Statistical heterogeneity was assessed using I2 statistics. Results Twelve studies (n = 2931 patients) were included in the final analysis. Nicorandil significantly reduced the CIN incidence (RR: 0.40 [0.31,0.52]; p < 0.00001), with consistent results for oral (RR: 0.35 [0.25,0.48]; p < 0.00001) and intravenous administration (RR: 0.52 [0.30,0.92]; p = 0.02) (p-interaction = 0.22). Oral nicorandil reduced the risk of major adverse events (RR: 0.71 [0.51,0.99]; p = 0.05). Among patients on nicorandil, serum creatinine levels were significantly lower at 48 h (SMD: −0.30 [−0.52,−0.07]; p = 0.009), and 72 h post-intervention (SMD: −0.42 [−0.71,−0.13]; p = 0.004). Nicorandil significantly reduced serum cystatin C levels at 48 h post-intervention (SMD: -0.56 [−1.01,−0.01]; p = 0.02). However, nicorandil did not significantly affect eGFR values at 24-h (SMD: 0.12 [−0.21,0.45]; p = 0.46), 48-h (SMD: 0.08 [−0.19,0.35]; p = 0.58), and 72-h (SMD: 0.34 [−0.13,0.81]; p = 0.16). Conclusion Nicorandil administration reduces the CIN incidence and improves renal biomarkers in patients undergoing CAG and PCI. Large-scale trials with longer follow-up periods are warranted to confirm renoprotective effects of nicorandil.
- 17 September 2024
- Published by Elsevier in Sleep Medicine
- Vol. 124, 146-153
Experiences and beliefs related to sleep paralysis among the general population of the twin cities: A cross-sectional study
- 17 September 2024
- Published by Elsevier in Sleep Medicine
- Vol. 124, 146-153
Experiences and beliefs related to sleep paralysis among the general population of the twin cities: A cross-sectional study